Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate)
- PMID: 1605902
- DOI: 10.2165/00002018-199207020-00008
Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate)
Abstract
The recommended regimen of etidronic acid (disodium etidronate) for the treatment of Paget's disease of bone is 5mg/kg/day for a period of less than six months. There have, however, been reports of impaired mineralisation of bone and concern that the risk of fracture is increased with this dosage. We report a patient with Paget's disease in whom fractures occurred through pagetic and non-pagetic bone which appeared to be causally related to treatment with lose doses of etidronic acid. The osteomalacia resolved when etidronic acid was discontinued.
Similar articles
-
Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.Morphologie. 2012 Aug;96(313):40-3. doi: 10.1016/j.morpho.2012.08.001. Epub 2012 Sep 27. Morphologie. 2012. PMID: 23022200
-
Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone.Aust N Z J Med. 1983 Jun;13(3):277-9. doi: 10.1111/j.1445-5994.1983.tb04658.x. Aust N Z J Med. 1983. PMID: 6416243
-
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease.Lancet. 1984 Apr 14;1(8381):821-4. doi: 10.1016/s0140-6736(84)92272-4. Lancet. 1984. PMID: 6143140
-
Etidronate disodium in the treatment of Paget's disease of bone.Ann Intern Med. 1982 May;96(5):619-25. doi: 10.7326/0003-4819-96-5-619. Ann Intern Med. 1982. PMID: 6280538 Review.
-
Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).Clin Orthop Relat Res. 1977;(127):94-105. Clin Orthop Relat Res. 1977. PMID: 410576 Review. No abstract available.
Cited by
-
Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.Drugs Aging. 2007;24(5):351-9. doi: 10.2165/00002512-200724050-00001. Drugs Aging. 2007. PMID: 17503893 Review.
-
Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs Aging. 1994 Dec;5(6):446-74. doi: 10.2165/00002512-199405060-00006. Drugs Aging. 1994. PMID: 7858370 Review.
-
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.Dig Dis Sci. 2002 Aug;47(8):1665-78. doi: 10.1023/a:1016495221567. Dig Dis Sci. 2002. PMID: 12184516 Review.
-
The role of bisphosphonates as adjuvant therapy for breast cancer.Curr Oncol Rep. 2001 Nov;3(6):506-15. doi: 10.1007/s11912-001-0072-x. Curr Oncol Rep. 2001. PMID: 11595119 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical